Symbiotec Pharmalab Limited (SYMBIOTEC)
₹1,260.00 -1.52% on 19 Oct, as of 12:25 IST · NSE
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Symbiotec Pharmalab's revenue was ₹218 Cr (+7.5% year on year, -11.0% on the previous quarter), and net profit ₹14.1 Cr (-53.1% year on year); the operating margin was 20.7%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹218 | +7.5% | -11.0% |
| Operating profit | ₹45.2 | -22.1% | -27.1% |
| Net profit | ₹14.1 | -53.1% | -49.8% |
| EPS (₹) | 2.24 | -95.2% | -49.0% |
| Operating margin | 20.7% | — | — |
SYMBIOTEC delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 39.61% of the SYMBIOTEC shares traded on NSE were taken to delivery, against the stock's own 20-session average of 31.22%. The price rose 1.96% on that unusually high delivery, the pattern the delivery dashboard labels accumulation.
Delivery in the last 5 sessions: 29.8% · 33.0% · 32.2% · 31.7% · 39.6%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Symbiotec Pharmalab Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited confirms the dematerialisation, mutilation, and cancellation of security certificates within prescribed timelines. This is a standard quarterly administrative filing with zero impact on operational or financial metrics.
- Compliance certificate filed pursuant to Regulation 74(5) of SEBI Regulations, 2018
- Covers the quarter ended September 30, 2026
- Issued by RTA MUFG Intime India Private Limited dated October 03, 2026
Symbiotec Pharmalab's wholly owned subsidiary, Knovea Pharmaceutical, has signed a definitive strategic commercialization agreement with an undisclosed leading global pharmaceutical company for two Dual Chamber Vial (DCV) injectable products in the United States. Knovea will handle development, regulatory filings, manufacturing, and supply, while the partner manages US distribution. The agreement includes milestone payments across development and regulatory stages, along with profit-sharing post-launch. The two target products address an estimated US addressable market of approximately $288 million, where currently only the innovator offers a DCV presentation.
- Exclusive US distribution agreement signed for 2 Dual Chamber Vial (DCV) injectable products
- Target products address an estimated US market size of approximately US$288 million
- Deal structured with development/regulatory milestone payments plus post-launch profit sharing
- Knovea responsible for development, US regulatory filings, manufacturing, and commercial supply
Symbiotec Pharmalab's wholly owned subsidiary, Knovea Pharmaceutical, has signed a definitive strategic commercialization agreement with an undisclosed leading global pharmaceutical company for two Dual Chamber Vial (DCV) injectable products in the United States. Knovea will handle development, regulatory filings, manufacturing, and supply, while the partner manages US distribution. The agreement includes milestone payments across development and regulatory stages, along with profit-sharing post-launch. The two target products address an estimated US addressable market of approximately $288 million, where currently only the innovator offers a DCV presentation.
- Exclusive US distribution agreement signed for 2 Dual Chamber Vial (DCV) injectable products
- Target products address an estimated US market size of approximately US$288 million
- Deal structured with development/regulatory milestone payments plus post-launch profit sharing
- Knovea responsible for development, US regulatory filings, manufacturing, and commercial supply
Symbiotec Pharmalab Limited has received an Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility located in Pithampur (SEZ), Madhya Pradesh. The regulatory inspection was conducted between August 10, 2026, and August 14, 2026. The U.S. FDA classified the inspection status as Voluntary Action Indicated (VAI), indicating successful closure of the inspection without critical regulatory roadblocks. This resolution ensures continuity of regulatory compliance for U.S. market supplies from this site.
- Received Establishment Inspection Report (EIR) from the U.S. FDA on September 29, 2026
- Facility inspected: Pithampur (SEZ), Madhya Pradesh, India
- Inspection period: August 10, 2026 to August 14, 2026
- Assigned Voluntary Action Indicated (VAI) classification, concluding the regulatory audit
Symbiotec Pharmalab has submitted the transcript for its Q1 FY27 earnings conference call held on September 22, 2026. The management highlighted that over 90% of its current fiscal year revenues come from its core steroid and hormone API business, which is expected to grow in high single digits. The company is diversifying into high-margin biotech fermentation CDMO and complex injectables platforms, aiming for these new verticals to constitute more than 50% of revenue in 5-6 years. Furthermore, nearly 70% of FY26 revenues were derived from relationships older than 7 years across 200+ global customers.
- Over 90% of current fiscal year annual revenue is estimated to come from the steroid hormones API business.
- Nearly 70% of FY26 revenues came from clients with customer relationships exceeding 7 years.
- Portfolio supported by 44 US DMFs and 25 European CEPs across 60 corticosteroid and hormone APIs.
- Long-term guidance envisions new CDMO and injectables verticals reducing the core API revenue share to less than 50% in 5-6 years.
- Industry peer benchmark EBITDA margins for complex CMO and injectables cited at above 35% with gross margins over 70%.
Symbiotec Pharmalab reported its first quarterly results as a listed entity for Q1FY27, with consolidated revenue rising 7.4% YoY to ₹218.2 crore from ₹203.2 crore. Consolidated EBITDA declined 22% YoY to ₹45.2 crore, and consolidated PAT dropped 52.8% to ₹14.1 crore, largely due to ₹35 crore in drag from pre-operating opex (₹23 crore) and depreciation (₹12 crore) on new businesses. Meanwhile, core API business operating revenue grew 6% YoY to ₹215.3 crore with steady EBITDA margins of ~30%. The company has planned a total gross capex of approx. ₹1,666 crore by end FY27, with revenue commercialization expected in the next 6-12 months.
- Consolidated revenue up 7.4% YoY to ₹218.2 cr, while consolidated PAT fell 52.8% YoY to ₹14.1 cr
- Pre-operating drag of ₹23 cr opex and ₹12 cr depreciation impacted consolidated profitability
- Core API operating revenue stood at ₹215.3 cr with EBITDA of ₹65.8 cr (~30% margin)
- Total estimated gross capex of approx. ₹1,666 cr by end-FY27 (~₹1,000 cr invested in new ventures)
- Net debt reduced from ~₹398 cr (as of June 30, 2026) to ~₹326 cr post-IPO proceeds on Sept 20, 2026
Symbiotec Pharmalab released its Q1FY27 investor presentation following its September 2026 listing at an IPO issue size of ₹1,757 crore (priced at ₹988 per share). Consolidated revenue grew 7% YoY to ₹218.2 crore, but net profit fell 53% YoY to ₹14.1 crore due to operational drag from pre-commercialization investments in new businesses. Operating expenses of ₹23.2 crore and depreciation of ₹11.6 crore from uncommissioned projects impacted reported margins. Over 60% of total capex (₹1,000+ crore out of ₹1,475 crore gross capex) is deployed in new ventures expected to start revenue generation over the next 6-12 months.
- Consolidated revenue up 7% YoY to ₹218.2 crore; reported PAT decreased 53% YoY to ₹14.1 crore
- New business drag included ₹23.2 crore in opex and ₹11.6 crore in depreciation for assets not yet yielding revenue
- Core API revenue grew 6% YoY to ₹215.3 crore with steady EBITDA margins of 31%
- Total gross capex stood at ₹1,475 crore as of June 30, 2026, with an estimated ₹1,666 crore by end of FY27
- First generic ANDA filed for Dual Chamber Vials (DCV) in the US market in September 2026
Symbiotec Pharmalab reported its unaudited financial results for the quarter ended June 30, 2026, marking its first post-IPO quarterly reporting following its September 1, 2026 stock exchange listing. For Q1 FY27, the company registered a standalone net loss of ₹156.90 million compared to a profit of ₹445.05 million in Q1 FY26. Total standalone expenses stood at ₹1,818.97 million against ₹1,663.29 million in the year-ago period. The company completed an IPO raising ₹1,500.00 million via fresh issue and ₹16,070.00 million through an offer for sale at an issue price of ₹988 per share.
- Standalone net loss stood at ₹156.90 million for Q1 FY27 compared to a net profit of ₹445.05 million in Q1 FY26
- Basic and diluted EPS dropped to negative ₹2.73 and ₹2.71 respectively for the quarter ended June 30, 2026
- Completed IPO of 17,786,442 equity shares at ₹988 per share, consisting of a ₹1,500.00 million fresh issue and ₹16,070.00 million OFS
- Total standalone expenses reached ₹1,818.97 million for Q1 FY27 versus ₹1,663.29 million in Q1 FY26
Symbiotec Pharmalab Limited released its financial results for the quarter ended June 30, 2026, marking its first quarterly reporting under SEBI LODR post-listing. Subsequent to the quarter-end, the company listed on NSE and BSE on September 1, 2026, following an IPO of 1,77,86,442 equity shares at Rs 988 per share, which included a fresh issue of Rs 1,500.00 million and an OFS of Rs 16,070.00 million. For comparison, FY26 consolidated revenue from operations stood at Rs 8,451.65 million with net profit of Rs 1,158.28 million. SRBC & CO LLP issued an unmodified limited review report on the consolidated results.
- Completed IPO of 1,77,86,442 shares at Rs 988 per share, listing on NSE/BSE on September 1, 2026
- IPO fresh issue aggregated to Rs 1,500.00 million, while OFS aggregated to Rs 16,070.00 million
- Consolidated FY26 full-year revenue stood at Rs 8,451.65 million and net profit at Rs 1,158.28 million
- Statutory auditor SRBC & CO LLP issued an unmodified limited review report
Symbiotec Pharmalab Limited submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) pursuant to Regulation 8(2) of the SEBI PIT Regulations. The filing follows an earlier intimation dated September 01, 2026. The policy document outlines procedures for uniform dissemination of price-sensitive data, handling of legitimate business information sharing, and appointment of the Chief Investor Relations Officer (CIRO). This is a routine regulatory compliance filing with no impact on business operations or financials.
- Filing submitted under Regulation 8(2) of SEBI (PIT) Regulations, 2015 on September 03, 2026
- Follows prior intimation dated September 01, 2026
- Fair Disclosure Policy original effective date noted as December 15, 2025
- Establishes protocols for UPSI dissemination and CIRO reporting lines to the CFO
Symbiotec Pharmalab Limited has submitted an intimation under Regulation 30(5) of the SEBI LODR Regulations, 2015. The company has authorized three Key Managerial Personnel (KMPs) to determine the materiality of events or information and make stock exchange disclosures. The authorized personnel comprise CMD Anil Satwani, CFO Raghavender Ramachandran, and CS Salil Jain.
- Disclosure filed pursuant to Regulation 30(5) of SEBI LODR Regulations, 2015 on September 01, 2026
- Authorized 3 Key Managerial Personnel to evaluate event materiality and stock exchange disclosures
- Designated KMPs include Chairman & MD Anil Satwani, CFO Raghavender Ramachandran, and CS Salil Jain
Symbiotec Pharmalab Limited has submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) to stock exchanges on September 01, 2026. The submission is made pursuant to Regulation 8(2) framed under Regulation 8(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is a standard regulatory compliance filing with no impact on operations or financials.
- Filing submitted under Regulation 8(2) of SEBI PIT Regulations, 2015
- Adoption of Code of Practices and Procedures for Fair Disclosure of UPSI
- Intimation dated September 01, 2026 submitted to BSE (544889) and NSE (SYMBIOTEC)
Symbiotec Pharmalab Limited has announced the closure of its trading window for all designated persons and their immediate relatives effective Tuesday, September 01, 2026. The window will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The company stated that the specific date of the Board of Directors meeting to approve the results will be communicated in due course.
- Trading window closure effective from Tuesday, September 01, 2026
- Closure applies to all designated persons and immediate relatives pursuant to SEBI PIT Regulations
- Trading window to reopen 48 hours after declaration of Q1 results for the quarter ended June 30, 2026
- Board meeting date to approve financial results to be intimated separately
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
